10-K: Kewaunee Scientific Reports Mixed Fiscal 2025 Results Amidst Strategic Nu Aire Acquisition

Kewaunee Scientific Corporation reported increased sales driven by its Nu Aire acquisition but experienced a decline in net earnings for fiscal year 2025, while maintaining a strong order backlog.

Summary

• Net sales for fiscal year 2025 increased to $240.5 million, up from $203.8 million in fiscal year 2024.
• Domestic segment sales rose by 30.7% to $179.4 million, primarily due to the acquisition of Nu Aire, Inc. on November 1, 2024.
• International segment sales decreased by 8.2% to $61.1 million, attributed to customer site delays in India.
• Gross profit margin improved to 28.6% in fiscal year 2025 from 25.5% in fiscal year 2024, driven by domestic operations, the Nu Aire acquisition, and cost-containment measures.
• Operating expenses increased significantly to $51.1 million (21.2% of sales) in fiscal year 2025 from $33.8 million (16.6% of sales) in fiscal year 2024, largely due to the Nu Aire acquisition, professional fees, and increased SG&A wages.
• Net earnings decreased to $11.405 million ($3.83 per diluted share) in fiscal year 2025, compared to $18.753 million ($6.38 per diluted share) for fiscal year 2024, primarily due to higher operating expenses and interest expense, despite the gross profit improvement.
• The order backlog stood at $214.6 million as of April 30, 2025, a substantial increase from $155.6 million at April 30, 2024, with an estimated 93% expected to ship during fiscal year 2026.
• The company successfully annuitized its pension obligation during fiscal year 2024, resulting in no pension expense in fiscal year 2025 compared to $4.177 million in the prior year.

Sentiment

Score: 6

Explanation: While the company achieved substantial sales growth and a strong backlog, primarily driven by a strategic acquisition, the significant decline in net earnings and diluted EPS due to increased operating and interest expenses, coupled with international segment delays, indicates a mixed financial performance. The acquisition presents long-term opportunities but also introduces integration risks and increased debt.

Positives

• Overall net sales increased by $36.7 million, or 18%, from fiscal year 2024 to fiscal year 2025, reaching $240.5 million.
• Domestic segment sales grew by 30.7% to $179.4 million, largely driven by the strategic acquisition of Nu Aire, Inc.
• Gross profit margin improved to 28.6% in fiscal year 2025 from 25.5% in fiscal year 2024, reflecting improved manufacturing productivity and effective cost-containment measures.
• Order backlog significantly increased to $214.6 million at April 30, 2025, from $155.6 million at April 30, 2024, indicating strong future revenue potential.
• The successful annuitization of the pension obligation in fiscal year 2024 eliminated future pension expense and administrative costs, contributing to $0 pension expense in fiscal year 2025.
• The Nu Aire acquisition expands the product portfolio to include biological safety cabinets, CO2 incubators, and ultralow freezers, and provides access to new distribution partners.
• Working capital increased to $64.7 million at April 30, 2025, from $56.0 million at April 30, 2024.
• Maintains a strong global management team and healthy end-use markets that continue to prioritize investment in projects requiring its products.

Negatives

• Net earnings decreased to $11.405 million in fiscal year 2025 from $18.753 million in fiscal year 2024, representing a 39.2% decline.
• Diluted earnings per share decreased to $3.83 in fiscal year 2025 from $6.38 in fiscal year 2024.
• Operating expenses increased substantially by $17.3 million, or 51.2%, to $51.1 million in fiscal year 2025, primarily due to the Nu Aire acquisition and associated integration costs.
• International segment sales decreased by 8.2% to $61.1 million due to customer site delays in India.
• Interest expense increased to $3.214 million in fiscal year 2025 from $1.799 million in fiscal year 2024 due to elevated borrowing levels related to the Nu Aire acquisition.
• Other income, net, decreased to $240,000 in fiscal year 2025 from $814,000 in fiscal year 2024, primarily due to lower interest earned on international cash balances and accelerated deferred financing costs.
• The current assets to current liabilities ratio slightly decreased to 2.2-to-1.0 at April 30, 2025, from 2.4-to-1.0 at April 30, 2024.

Risks

• Loss of a large customer could materially affect revenues and profits, as sales to two domestic dealers and a national stocking distributor accounted for approximately 41% of sales in fiscal year 2025.
• Inability to retain or motivate key management and highly skilled personnel, hire qualified personnel, or adapt corporate culture could adversely affect growth and operations.
• Information technology system failures and network disruptions, including cybersecurity incidents, could prevent access to cloud-based systems, interfere with transactions, impede manufacturing/shipping, and damage reputation.
• The share repurchase program may not enhance long-term stockholder value or successfully mitigate the dilutive effect of employee equity awards.
• Failure to realize anticipated benefits from the Nu Aire acquisition due to integration difficulties, failure of the acquired business to perform as expected, failure to achieve synergies, or loss of customers/key employees.
• Goodwill ($12.5 million) and other intangible assets ($17.8 million) recorded in connection with the Nu Aire acquisition could become impaired, adversely affecting future operating results.
• Challenges in incorporating additional internal controls for Nu Aire, which was not previously subject to Sarbanes-Oxley requirements, could lead to significant deficiencies or material weaknesses in internal control over financial reporting.
• Exposure to risks inherent in international sales, including geopolitical tensions, local acceptance of products, political instability, currency controls, changes in import/export regulations, tariffs, and foreign exchange rate fluctuations (29% of FY2025 revenues from outside the U.S.).
• Intense competition in the industry, with competitive pricing, new product introductions, or negative perceptions of product quality potentially leading to declines in revenue and profit margins.
• Increases in raw material costs (steel, wood, epoxy resin) could negatively affect sales and profits, as prices are often quoted on a firm basis for extended future delivery dates.
• Events outside the company's control, such as customer rescheduling, construction delays, weather conditions, political, and economic events, can affect the timing of customer orders and operating results.
• Volatility in the laboratory and healthcare building construction industry, which is the company's principal market, could materially and adversely affect business and financial condition.
• Changes in U.S. political or regulatory environment could affect the availability of government funding, impacting customers who rely on such programs (e.g., medical research grants).
• Manufacturing and supply chain risks, including reliance on sole or limited sources of supply, supplier difficulties, and disruptions from external events like natural disasters or pandemics.
• Disruptions in financial markets could create uncertainty in economic conditions, adversely affecting customer demand, sales, pricing, and profitability.
• Future growth depends on penetrating new international markets, which involves navigating different laws, regulations, construction customs, and standards.
• Compliance with global laws and regulations (economic sanctions, export, anti-corruption, tax laws) is complex, and failure to comply could have a material adverse impact.
• Changes in U.S. trade policy, including tariffs, could increase costs, reduce demand, or lower profit margins.
• Evolving expectations related to environmental, social, and governance (ESG) considerations could expose the company to liabilities, increased costs, and reputational harm.
• Stock price volatility due to various factors, including operating results, technological innovations, industry conditions, and low trading volume.
• Future issuances of common stock could dilute existing stockholders' ownership.
• Cash assets held at financial institutions may exceed FDIC insurance coverage, posing a risk of loss in case of financial institution failure.
• The impact of future pandemics remains highly uncertain and could affect business operations, workforce, customer demand, and access to capital.
• Strategic acquisitions carry general risks, including diversion of management attention, integration difficulties, failure to achieve synergies, and unanticipated expenses or liabilities.

Future Outlook

The company anticipates continued growth, driven by the strategic acquisition of Nu Aire, a strong global management team, a healthy order backlog, and improved manufacturing capabilities. Demand for products remains dependent on laboratory and healthcare construction projects and fluctuations in prevailing pricing and raw material costs. The company is well-positioned due to end-use markets continuing to prioritize investment in projects that require the products it designs and manufactures.

Management Comments

• Kewaunee's fiscal year 2025 results are a testament to the consistent execution and dedication of the global team, as well as the strong relationships with dealers and distribution channel partners, who bring solutions to customers across multiple end markets.
• The strong global management team, healthy backlog, improved manufacturing capabilities, and end-use markets that continue to prioritize investment in projects that require the products Kewaunee designs and manufactures, positions the Company well.
• Open and honest communication among team members, managers, and leaders helps create a collaborative work environment where everyone can contribute, grow, and succeed.

Industry Context

Kewaunee Scientific operates in a highly competitive laboratory and healthcare furniture industry, where competitive public bidding is common. The industry is characterized by customer orders requiring extended future delivery dates due to products being installed in buildings yet to be constructed, leading to potential delays and cost burdens from raw material price increases. The acquisition of Nu Aire, a leader in biological safety cabinets and other lab equipment, positions Kewaunee to expand its capabilities and market leadership in laboratory furnishings, aligning with broader industry trends of integrated lab solutions and specialized equipment. The company's reliance on government funding for some customers (e.g., medical research grants) ties its performance to political and economic factors affecting public sector investments in research and healthcare infrastructure.

Comparison to Industry Standards

• The document identifies the laboratory and healthcare furniture industries as "highly competitive," with "price, product performance, and customer service" as principal deciding factors.
• No specific comparable companies, projects, or detailed industry benchmarks are provided within this filing to allow for a direct assessment of Kewaunee's results against global industry standards.

Corporate Governance

Legal Proceedings

• Involved in disputes and litigation relating to claims arising out of operations in the ordinary course of business.
• Periodically subject to government audits and inspections.
• Management believes that any such matters presently pending will not, individually or in the aggregate, have a material adverse effect on results of operations or financial condition.

Stakeholder Impact

• Shareholders experienced a decrease in net earnings and diluted EPS, but benefit from increased sales and a strong backlog. The share repurchase program aims to offset dilution and potentially enhance value. Future stock issuances could lead to dilution.
• Employees saw an increase in the domestic workforce to 793 employees due to the Nu Aire acquisition. The company emphasizes creating a fulfilling work environment with competitive benefits, career growth, and health resources. Retention of key personnel is identified as a risk.
• Customers may experience delivery delays due to construction schedules or international site issues. They benefit from an expanded product portfolio through the Nu Aire acquisition, offering a broader range of laboratory furnishings and biosafety solutions.
• Suppliers are critical for raw materials, and while the company uses multiple suppliers, reliance on sole or limited sources for certain items makes it vulnerable to supplier difficulties or disruptions.
• Creditors face increased indebtedness due to the Nu Aire acquisition, with new term loans and seller notes. The company reports compliance with financial covenants under its Loan Agreement.

Next Steps

• Complete the purchase price allocation for the Nu Aire acquisition, expected no later than one year from the Closing Date (November 1, 2024).
• Integrate Nu Aire into the company's systems and control environment.
• Continue to invest in recruiting talented people to technical and non-technical roles.
• Fund anticipated capital expenditures of approximately $7.0 million in fiscal year 2026, primarily through operating activities and revolving credit facility borrowings.
• Collect the majority of April 30, 2025 accounts receivable balances during the first quarter of fiscal year 2026.
• Adopt ASU 2023-09 (Income Tax Disclosures) in fiscal year 2026.
• Adopt ASU 2024-03 (Expense Disaggregation Disclosures) for annual disclosures in fiscal year 2028 and for interim disclosures in fiscal year 2029.
• The Board of Directors will determine the declaration and payment of any future dividends based on various factors.
• Management will continue to assess capital needs, market price, and general market conditions for future share repurchases under the amended program.

Key Dates

Recommendation

Keywords

Laboratory furniture, Healthcare furniture, Technical furniture, Laboratory equipment, Biological safety cabinets, Fume hoods, Casework, Lab design, Lab manufacturing, SEC filing, 10-K, Financial results, Acquisition, Nu Aire, KEQU, Statesville, North Carolina, India, Singapore, Corporate governance, Risk management, Supply chain, Financial performance, Backlog, Earnings, Revenue, Profitability, Capital expenditures, Share repurchase